Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that Scott Braunstein, M.D., Chief Executive Officer and Joseph Hulihan, M.D., Chief Medical Officer will p...
Today, we post our first research on Marinus Pharmaceutics, a biopharma name deep in 'Busted IPO' territory. The company is entering into a critical phase of development, has recently shored up its finances and has seen recent positive analyst commentary. An analysis around Marinu...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it plans to release financial results for the fourth quarter and fiscal year ended December 31, 2020 before...
Marinus Pharmaceuticals (MRNS) has enrolled the first patient in a Phase 3 (RAISE trial) evaluating IV ganaxolone for the treatment of refractory status epilepticus ((RSE)), an occurrence of continued or intermittent seizures lasting more than five minutes in duration without recovery of...
Marinus and Ceribell, Inc. agree to place handheld Ceribell Rapid Response EEG systems in hospitals in connection with its Phase 3 RSE clinical trial Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therape...
Marinus Pharmaceuticals (MRNS) gains 7% in premarket in reaction to a positive response from the FDA, that the efficacy and safety data resulting from the company’s Phase 3 Marigold study evaluating oral ganaxolone in children and young adults with CDKL5 deficiency ...
Marinus is moving towards a pre-NDA meeting, targeted for the end of Q1, in support of NDA submission by the end of Q2 Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure di...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Con...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to...
On Tuesday, shares of up-and-coming biotechs Marinus Pharmaceuticals (NASDAQ: MRNS) , iBio (NYSEMKT: IBIO) , and Arcturus Therapeutics Holdings (NASDAQ: ARCT) fell by 12%, 13%, and 19%, respectively. One common catalyst seems to be the secondary-share issues anno...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...